Abvc Biopharma Inc (ABVC)
$0.66
+0.01
(+1.23%)▲
Performance
- $0.65$0.66$0.66
2.27%
Downside
Day's Volatility :2.27%
Upside
0.0%
- $0.60$3.35$0.66
9.09%
Downside
52 Weeks Volatility :82.09%
Upside
80.3%
Returns
| Period | Abvc Biopharma Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -15.19% | 0.0% |
6 Months | -47.28% | 0.0% |
1 Year | -39.54% | 0.0% |
3 Years | -98.21% | -22.3% |
Highlights
Market Capitalization | 8.2M |
Book Value | $0.71 |
Earnings Per Share (EPS) | -1.66 |
Wall Street Target Price | 2.02 |
Profit Margin | 0.0% |
Operating Margin TTM | -833.72% |
Return On Assets TTM | -44.55% |
Return On Equity TTM | -320.36% |
Revenue TTM | 136.4K |
Revenue Per Share TTM | 0.02 |
Quarterly Revenue Growth YOY | 1817.5% |
Gross Profit TTM | 350.7K |
EBITDA | -8.5M |
Diluted Eps TTM | -1.66 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 206.06%
Technicals Summary
Sell
Neutral
Buy
Abvc Biopharma Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Abvc Biopharma Inc | -2.2% | -47.28% | -39.54% | -98.21% | -97.8% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Abvc Biopharma Inc | NA | NA | NA | 0.0 | -3.2 | -0.45 | NA | 0.71 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Abvc Biopharma Inc | Sell | $8.2M | -97.8% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Abvc Biopharma Inc
Increasing Revenue
Revenue is up for the last 2 quarters, 1.20K → 117.14K (in $), with an average increase of 99.0% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -3.93M → -1.01M (in $), with an average increase of 288.4% per quarter
Vs REGN
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 76.6%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 167.4%
Institutional Holdings
Vanguard Group Inc
0.39%Honkamp Krueger Financial Services Inc
0.32%Geode Capital Management, LLC
0.18%Northern Trust Corp
0.16%Bank of America Corp
0.04%Tower Research Capital LLC
0.02%
Company Information
american brivision (holding) corporation, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the united states. the company is developing abv-1501, a combination therapy for triple negative breast cancer; abv-1504 for major depressive disorders; abv-1505 for attention deficit hyperactivity disorder; abv-1703 for the treatment of pancreatic cancer; abv-1702 to treat myelodysplastic syndromes; and abv-1601 for treating depression in cancer patients. it has a co-development agreement with rgene corporation; collaboration agreement with biohopeking corporation to develop abv-1501; and collaborative agreement with biofirst corporation to co-develop bfc-1401 vitreous substitute for vitrectom; and license with biofirst corporation to research and develop a medical device, abv-1701 vitargus for the treatment of retinal detachment or vitreous hemorrhage. the company was founded in 2015 and is based in fremont, california. american br
Organization | Abvc Biopharma Inc |
Employees | 16 |
CEO | Mr. Eugene Jiang |
Industry | Industrial Specialties |
Discover More
A Spac I Acquisition Corp
$0.66
+1.23%
Keyarch Acquisition Corp
$0.66
+1.23%
Connexa Sports Technologies Inc
$0.66
+1.23%
Us Value Etf
$0.66
+1.23%
First Wave Biopharma Inc
$0.66
+1.23%
Global X Msci Next Emerging
$0.66
+1.23%
Fat Projects Acquisition Corp
$0.66
+1.23%
Capital Link Global Fintech
$0.66
+1.23%
Applied Uv Inc
$0.66
+1.23%